Track topics on Twitter Track topics that are important to you
IDAHO FALLS, Idaho, Aug. 9, 2017 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") announces that it has obtained several significant contracts for Radiological Field Services that are to be completed during the remainder of 2017. The Company reports these contracts are both with the U.S. Department of Energy (DOE) and the International Atomic Energy Agency (IAEA) for work within the U.S. and in South America. All of the contract work will involve performing source removals from inactive radiation therapy devices and shipping these devices to secure locations for storage and disposal.
Steve T. Laflin, President and CEO of the Company, said, "The Company has been continuing to build upon our radiological field service experience and equipment capability for performing these types of activities for several years. The Company has continued to build a reputation for safe, cost-effective, on-time completion of these services, and these recent contract awards are a further recognition of that capability. We have an outstanding group of technicians and engineers that have a real talent for performing these types of activities and the Company's development of a mobile hot cell offers us a real competitive advantage. We anticipate the new contract work is anticipated to be completed in 2017, which should result in approximately a 120% increase in the Radiological Services segment revenue for the year end 2017 compared to the same period in 2016."
About International Isotopes Inc.
International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards and provides radiochemicals for pharmacy compounding, clinical research, and life sciences. The Company also produces bulk cobalt-60 and manufactures a variety of cobalt-60 products such as teletherapy sources, and provides a wide range of radiological field services on a contract basis to clients.
International Isotopes Inc. Safe Harbor Statement
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, but not limited to, statements with respect to revenue performance within any of the Company's business segments and the success of new products or contract opportunities. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including our Annual Report on Form 10-K for the year ended December 31, 2016. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
For more information, please visit the Company web site: www.internationalisotopes.com
SOURCE International Isotopes Inc.NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...